Tegilerdine

Preclinical

TThe First People's Hospital of Lianyungang

Tegilerdine is one of 3 therapeutic programs targeting General Anesthetic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

General AnestheticRecruiting

General AnestheticPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in General Anesthetic

#DrugCompanyPhaseTrials

Sufenta

LLeaf Vertical Inc.

Preclinical

1 2

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 3

Tegilerdine

TThe First People's Hospital of Lianyungang

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

General Anesthetic

NCT07323043

Clinical

Trials by Indication[1]

General Anesthetic1 trial

The Affiliated Lianyungang Hospital of Xuzhou Medical University

Recruiting·TThe First People's Hospital of Lianyungang·Preclinical·NCT07323043·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tegilerdine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tegilerdine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The First People's Hospital of Lianyungang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TThe First People's Hospital of Lianyungang

Tegilerdine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

General Anesthetic1 trial

References

Drug Info

Quick Facts

Related News